The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial
Open accessAbstract
Background Lowering of LDL cholesterol reduces major vascular events, but whether more intensive therapy safely produces extra benefits is uncertain. We aimed to establish efficacy and safety of more intensive statin treatment in patients at high cardiovascular risk.Methods We undertook a double-blind randomised trial in 12,064 men and women aged 18-80 years with a history of myocardial infarction. Participants were either currently on or had clear indication for statin therapy, and had a total cholesterol concentration of at least 3·5 mmol/L if already on a statin or 4·5 mmol/L if not. Randomisation to either 80 mg or 20 mg simvastatin daily was done centrally using a minimisation algorithm. Participants were assessed at 2, 4, 8, and 12 months after randomisation and then every 6 months until final follow-up. The primary endpoint was major vascular events, defined as coronary death, myocardial infarction, stroke, or arterial revascularisation. Analysis was by intention to treat. This study is registered, number ISRCTN74348595.Findings 6031 participants were allocated 80 mg simvastatin daily, and 6033 allocated 20 mg simvastatin daily. During a mean follow-up of 6·7 (SD 1·5) years, allocation to 80 mg simvastatin produced an average 0·35 (SE 0·01) mmol/L greater reduction in LDL cholesterol compared with allocation to 20 mg. Major vascular events occurred in 1477 (24·5%) participants allocated 80 mg simvastatin versus 1553 (25·7%) of those allocated 20 mg, corresponding to a 6% proportional reduction (risk ratio 0·94, 95% CI 0·88-1·01; p=0·10). There were no apparent differences in numbers of haemorrhagic strokes (24 [0·4%] vs 25 [0·4%]) or deaths attributed to vascular (565 [9·4%] vs 572 [9·5%]) or non-vascular (399 [6·6%] vs 398 [6·6%]) causes. Compared with two (0·03%) cases of myopathy in patients taking 20 mg simvastatin daily, there were 53 (0·9%) cases in the 80 mg group.Interpretation The 6% (SE 3·5%) reduction in major vascular events with a further 0·35 mmol/L reduction in LDL cholesterol in our trial is consistent with previous trials. Myopathy was increased with 80 mg simvastatin daily, but intensive lowering of LDL cholesterol can be achieved safely with other regimens.Funding Merck; The Clinical Trial Service Unit also receives funding from the UK Medical Research Council and the British Heart Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“based on the results of the SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine) trial the US Food and Drug Administration has announced new safety recommendations for high-dose simvastatin treatment owing to an associated elevated risk of muscle injury or myopathy75.”
From Perspectives and opportunities for nanomedicine in the management of atherosclerosis (2011) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,638
Cited by
Sorted by citations
Items 501–557 of 557
Adjuvant Therapy for Incremental Low-Density Lipoprotein Cholesterol Reduction With Ezetimibe
Fernández‐Liz, E., Colomer, M. E. B., Bendahan, G., Roch, M., & Vallés, J. (2017) · Clinical Medicine Insights Therapeutics · doi:10.1177/1179559x17695550
Uso de estatinas em pacientes com doença isquêmica do coração: análise de custo-efetividade
Luque, A. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2017.tde-06032017-102120
Naugler, C. T., & Sidhu, D. (2014) · Canadian Family Physician
Malecki-Ketchell, A. (2017) · doi:10.1057/978-1-137-46552-8_7
Islam, S. A., Danwada, R., Ganguli, M., Espaillat, R., Jarvis, M. F., & Bacher, H. P. (2017) · Journal of Pharmacy Technology · doi:10.1177/8755122517745650
Skeletal Muscle Mitochondrial Toxicity
Herbert, E. K., Herbert, S., & Herbert, K. E. (2018) · Wiley eBooks · doi:10.1002/9781119329725.ch8 · Cited by 1
Rosenwasser, R., Anderson, K., & Epstein, B. J. (2013) · doi:10.2217/ebo.12.428
Ottomani, H., Moulin, P., Malet, L., & Aulagner, G. (2018) · Elsevier eBooks · doi:10.1016/b978-2-294-75077-9.00009-8
HYPOLIPIDEMIC THERAPY BY STATINS IN ACUTE CORONARY SYNDROME
Tsibulskaya, N. Y., Kharkov, E. I., & Петрова, М. М. (2018) · Siberian medical review · doi:10.20333/2500136-2018-6-22-32
“Наблюдение за пациентами составило в среднем 6-7 лет и показало, что наибольшая частота развития миопатии регистрируется в первый год терапии статинами [8].”
Vanajakshamma, V., Kasala, L., & Chanda, N. (2019) · Indian Journal of Cardiovascular Disease in Women · doi:10.1055/s-0039-1697076
The New ACC/AHA Cholesterol Guideline: A Significant Change with Significant Implications
Nijjar, P. S., Miedema, M. D., & Duprez, D. A. (2014)
Statins: Side effects and drug interactions
Kažić, T. (2011) · Scripta Medica · doi:10.5937/scrimed1102084k
Differential response trajectories to acute exercise in blood and musclePreprint
Amar, D., Lindholm, M., Norrbom, J., Wheeler, M., Rivas, M., & Ashley, E. (2019) · bioRxiv · doi:10.1101/863100
“…lower plasma LDL cholesterol, which is essential for preventing cardiovascular disease (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group et al., 2010), and is a well-established effect of exercise training (Albarrati et al., 2018).”
BackgroundGenetic Risk Factors for Statin-Associated Muscle Symptoms (SAMS)
Rosario-Berrios, A. N., Duconge-Soler, J., & Ruaño, G. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-33304-1_11
Statins in primary prevention: is the enthusiasm justified?
Chopra, A. K., & Yadav, R. K. (2020) · Indian Heart Journal · doi:10.1016/j.ihj.2020.07.021
Pedro‐Botet, J., Climent, E., & Benaiges, D. (2020) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(20)30024-8
An Overview on the Role of Statins in Dyslipidemia Management in Primary Health Care
Albahrani, K. A., Alrushud, S. S., Albulaihed, A. K., Alqahtani, D. S. F., Aloush, K. M., Alshanqiti, H. M. A., Ghandorah, R., AlMalki, Y., Battash, O. I., & Alolah, A. A. (2021) · World Journal of Environmental Biosciences · doi:10.51847/p2ebehdqdf
“The Scandinavian Simvastatin Survival Study, published in 1994, demonstrated the value of statins in individuals with known vascular disease (Armitage et al ., 2010; CTT, 2010).”
InfluentialKardiovaskuläre Prophylaxe: Wenn man Surrogatmarker „therapiert“
Erdmann, E. (2015) · Deutsches Ärzteblatt · doi:10.3238/perskardio.2015.09.18.08
Complications of Pediatric Renal Transplantation
Dharnidharka, V. R., & Araya, C. E. (2015) · Springer eBooks · doi:10.1007/978-3-642-27843-3_67-1
Toth, P. P. (2018) · Contemporary cardiology · doi:10.1007/978-3-319-97622-8_3
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.01451-7
Khan, N., & Williams, H. (2015) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2015.10.8.394
4th Asian Preventive Cardiology And Cardiac Rehabilitation Conference
(2012) · Journal of the Hong Kong College of Cardiology · doi:10.55503/2790-6744.1052
Galinovskaya, N. V., Усова, Н. Н., & Latysheva, V. Y. (2013) · Health and Ecology Issues · doi:10.51523/2708-6011.2013-10-4-4
Schaefer, J., & Jackson, S. (2022) · Springer eBooks · doi:10.1007/978-3-031-06731-0_8
(2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2022.13.pr4
(2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2022.13.pr3
(2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2022.13.pr7
(2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2022.13.pr2
(2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2022.13.pr8
(2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2022.13.pr6
Gill, D. (2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2022.13.pr5
Gill, D. (2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2022.13.pr1
Schwartz, G. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00036-4
Simvastatin – welche Dosierung?
Enthaler, N. (2011) · Zeitschrift für Allgemeinmedizin · doi:10.1007/bf03652557
Pharmacogenomics in Cardiovascular Diseases
Kekić, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-45903-0_11
Schwartz, G. G., & Do, R. Q. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00039-6
Oral semaglutide improves glycemic control and lowers blood lipids: evidence from a real-world study
Gašparini, D., Čakanić, F., Tufekčić, T., Rasnek, D., Wensveen, F. M., & Wensveen, T. T. (2024) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000312 · Cited by 1
CDA-AMC (2024) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2024.1040
Ghosh, A. (2023) · Journal of Applied Biochemistry & Laboratory Medicine · doi:10.5005/jablm-11031-04102
A Revolution in Medicine and Surgery Has Begun
Spector, R. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.02.012
Popiołek-Kalisz, J. (2025) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2025.500846
LDL-Cholesterin: Wie weit sollen wir es denn senken?
Egidi, G. (2025) · Zeitschrift für Allgemeinmedizin · doi:10.1007/s44266-025-00449-z
Popiołek-Kalisz, J. (2025) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.500846
Medical Management of Serum Lipids and Coronary Heart Disease
Ababneh, B. A., Dadu, R. T., Pokharel, Y., Jones, P. H., & Ballantyne, C. M. (2015) · Cardiovascular medicine · doi:10.1007/978-1-4471-2828-1_3
Saisa, D., Mustika, S., Fachrureza, M., Surya, S. C., Rampengan, D. D. C. H., Lele, J. A. J. M. N., Nojaid, A., & Hogipranata, M. O. (2025) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003110
Tomlinson, B. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2642210 · Cited by 1
Hourcade‐Potelleret, F. (2012) · theses.fr (ABES) · doi:10.70675/e78e3f4az1aadz47d6z9a8bz8dd0e636d743
Kimura, T., Watanabe, H., Morimoto, T., Natsuaki, M., Yamamoto, K., Obayashi, Y., Nishikawa, R., Andò, K., Suwa, S., Isawa, T., et al. (2026) · Circulation Reports · doi:10.1253/circrep.cr-26-0051
Dimmitt, S. B., Stampfer, H. G., Kennedy, M., & Martin, J. H. (2026) · Heart Lung and Circulation · doi:10.1016/j.hlc.2026.01.012
Xue, Q., Wang, F., Zhang, Y., & Chen, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1867316
“…2016; Freeman et al., 2001; Collins et al., 2003; Keech et al., 2003; Sever et al., 2004; Kjekshus et al., 2007; Chan et al., 2010; Ridker et al., 2012; Ong et al., 2014; Erlandson et al., 2015; Lee et al., 2020; Zheng et al., 2022; Grinspoon et al., 2023; Hong et al., 2024; Armitage et al., 2010).”
Non-statin Therapies for CKD with Dyslipidemia
Mucsi, I. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0515-7_9
“However, a review of recent RCTs revealed a substantial CVD event rate in those treated to achieve even the most stringent LDL-C targets [ 64 – 66 ].”
Background
Metadata
- Authors
- Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group
- Corresponding author
- Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2010-11
- Volume
- 376
- Issue
- 9753
- Pages
- 1658-1669
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC2988223
- OpenAlex
- W1523152575
- Cited by
- 558
- References
- 38
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 20 · 2023: 23 · 2022: 28 · 2021: 22 · 2020: 29 · 2019: 31 · 2018: 33 · 2017: 35 · 2016: 40 · 2015: 47 · 2014: 52 · 2013: 50 · 2012: 68
- FWCI
- 61.00
- Type
- journal article
- Language
- en
- Update notices
- erratum (2011-01-08)
- Open access
- bronze
- doi.org
- Locations
- The Lancet (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Funders
- British Heart Foundation (PG/12/32/29544)
- University of Southampton
- University of Oxford
- Medical Research Council (MC_EX_G0801669)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- simvastatin, LDL cholesterol lowering, high-intensity statin therapy, myocardial infarction survivors, major vascular events, coronary artery disease, stroke, cardiovascular mortality, statin safety, lipid-lowering therapy, high cardiovascular risk patients, dose comparison, hemorrhagic stroke, coronary death, myocardial infarction recurrence, secondary prevention
- MeSH terms
- Adult, Aged, Aged, 80 and over, Anticholesteremic Agents, Double-Blind Method, Female, Humans, Hypercholesterolemia, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Triglycerides, Simvastatin, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
